NASDAQ:LUNG Pulmonx (LUNG) Stock Price, News & Analysis $7.31 +0.37 (+5.33%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$6.74▼$7.3550-Day Range$5.59▼$8.4252-Week Range$5.46▼$14.84Volume330,179 shsAverage Volume439,163 shsMarket Capitalization$283.74 millionP/E RatioN/ADividend YieldN/APrice Target$14.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Pulmonx alerts: Email Address Pulmonx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside102.9% Upside$14.83 Price TargetShort InterestHealthy4.11% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 8 Articles This WeekInsider TradingAcquiring Shares$97,436 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($1.64) to ($1.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.37 out of 5 starsMedical Sector277th out of 910 stocksSurgical & Medical Instruments Industry36th out of 95 stocks 3.4 Analyst's Opinion Consensus RatingPulmonx has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoveragePulmonx has only been the subject of 2 research reports in the past 90 days.Read more about Pulmonx's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted4.11% of the float of Pulmonx has been sold short.Short Interest Ratio / Days to CoverPulmonx has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pulmonx has recently decreased by 8.23%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPulmonx does not currently pay a dividend.Dividend GrowthPulmonx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LUNG. Previous Next 2.7 News and Social Media Coverage News SentimentPulmonx has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Pulmonx this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Pulmonx to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Pulmonx insiders have bought 27.22% more of their company's stock than they have sold. Specifically, they have bought $97,436.00 in company stock and sold $76,587.00 in company stock.Percentage Held by InsidersOnly 5.70% of the stock of Pulmonx is held by insiders.Percentage Held by Institutions91.04% of the stock of Pulmonx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pulmonx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Pulmonx are expected to grow in the coming year, from ($1.64) to ($1.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pulmonx is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pulmonx is -4.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPulmonx has a P/B Ratio of 2.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Pulmonx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Pulmonx Stock (NASDAQ:LUNG)Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Read More LUNG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LUNG Stock News HeadlinesSeptember 6 at 9:32 AM | insidertrades.comGeoffrey Beran Rose Sells 4,586 Shares of Pulmonx Co. (NASDAQ:LUNG) StockAugust 23, 2024 | insidertrades.comSteven S. Williamson Acquires 14,245 Shares of Pulmonx Co. (NASDAQ:LUNG) StockSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …September 2, 2024 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) Sees Significant Drop in Short InterestAugust 31, 2024 | markets.businessinsider.comAeriseal’s Market Potential and Safety Profile: Justifying a Hold Rating for PulmonxAugust 29, 2024 | finance.yahoo.comPulmonx to Participate in the Lake Street 8th Annual Best Ideas Growth ConferenceAugust 28, 2024 | americanbankingnews.comPulmonx Co. (NASDAQ:LUNG) CEO Purchases $97,435.80 in StockAugust 22, 2024 | globenewswire.comPulmonx to Present at the 2024 Wells Fargo Healthcare ConferenceSeptember 7, 2024 | Weiss Ratings (Ad)What is Nvidia’s New $1 Trillion SuperProject?Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …August 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Pulmonx: Strong Growth and Promising Clinical AdvancementsAugust 7, 2024 | uk.investing.comPulmonx stock hits 52-week low at $5.67 amid market challengesAugust 2, 2024 | finance.yahoo.comAnalysts Are Updating Their Pulmonx Corporation (NASDAQ:LUNG) Estimates After Its Second-Quarter ResultsJuly 31, 2024 | globenewswire.comPulmonx Reports Second Quarter 2024 Financial ResultsJuly 29, 2024 | globenewswire.comPulmonx to Present at the Canaccord Genuity 44th Annual Growth ConferenceJuly 26, 2024 | finance.yahoo.comPulmonx Corporation (LUNG)July 21, 2024 | seekingalpha.comPulmonx: Low Bar For Q2 EarningsJuly 10, 2024 | globenewswire.comPulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024May 6, 2024 | globenewswire.comPulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive LUNG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pulmonx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:LUNG CUSIPN/A CIK1127537 Webpulmonx.com Phone1-650-364-0400FaxN/AEmployees250Year FoundedN/APrice Target and Rating Average Stock Price Target$14.83 High Stock Price Target$17.00 Low Stock Price Target$10.00 Potential Upside/Downside+102.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,840,000.00 Net Margins-75.56% Pretax Margin-74.80% Return on Equity-50.79% Return on Assets-33.06% Debt Debt-to-Equity Ratio0.37 Current Ratio8.97 Quick Ratio7.92 Sales & Book Value Annual Sales$76.58 million Price / Sales3.71 Cash FlowN/A Price / Cash FlowN/A Book Value$2.58 per share Price / Book2.83Miscellaneous Outstanding Shares38,816,000Free Float36,603,000Market Cap$283.74 million OptionableOptionable Beta0.63 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. David A. Lehman (Age 63)General Counsel & Secretary Comp: $651.39kMr. Geoffrey Beran Rose (Age 50)Chief Commercial Officer Comp: $632.29kMr. Steven S. Williamson (Age 51)CEO, President & Director Mr. Mehul Joshi (Age 63)Chief Financial Officer Mr. Sri RadhakrishnanChief Technical OfficerMs. Marcee M. Maroney (Age 54)Vice President of Marketing Sarah HuberVice President of Sales (U.S.)Ms. Lisa Paul (Age 60)Chief People Officer Mr. Jérôme ErathSenior VP & GM of Europe Middle-East & AfricaMr. John B. McKune (Age 48)VP & Corporate Controller More ExecutivesKey CompetitorsInovio PharmaceuticalsNASDAQ:INOCerusNASDAQ:CERSAtrionNASDAQ:ATRICardiovascular SystemsNASDAQ:CSIIEmbectaNASDAQ:EMBCView All CompetitorsInsiders & InstitutionsGeoffrey Beran RoseSold 4,586 sharesTotal: $30,726.20 ($6.70/share)David Aaron LehmanSold 5,765 sharesTotal: $38,567.85 ($6.69/share)Steven S WilliamsonBought 14,245 shares on 8/20/2024Total: $97,435.80 ($6.84/share)Point72 Asset Management L.P.Sold 2,474,183 shares on 8/19/2024Ownership: 0.621%Algert Global LLCSold 36,564 shares on 8/16/2024Ownership: 0.054%View All Insider TransactionsView All Institutional Transactions LUNG Stock Analysis - Frequently Asked Questions How have LUNG shares performed this year? Pulmonx's stock was trading at $12.75 at the start of the year. Since then, LUNG shares have decreased by 42.7% and is now trading at $7.31. View the best growth stocks for 2024 here. How were Pulmonx's earnings last quarter? Pulmonx Co. (NASDAQ:LUNG) posted its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.36) earnings per share for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The business earned $18.85 million during the quarter, compared to analyst estimates of $17.54 million. Pulmonx had a negative net margin of 75.56% and a negative trailing twelve-month return on equity of 50.79%. When did Pulmonx IPO? Pulmonx (LUNG) raised $100 million in an initial public offering on Thursday, October 1st 2020. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Stifel, Wells Fargo Securities and Canaccord Genuity were co-managers. Who are Pulmonx's major shareholders? Top institutional investors of Pulmonx include Primecap Management Co. CA (14.71%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (2.73%), Victory Capital Management Inc. (2.15%) and Millennium Management LLC (1.16%). Insiders that own company stock include Glendon E French III, Derrick Sung, Geoffrey Beran Rose, David Aaron Lehman, John Mckune, Richard Ferrari and Alissa Hsu Lynch. View institutional ownership trends. How do I buy shares of Pulmonx? Shares of LUNG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LUNG) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pulmonx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pulmonx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
